The Latin America, Middle East and Africa Leukemia Therapeutics Market would witness market growth of 9.2% CAGR during the forecast period (2023-2029).
The demand for leukemia treatments is projected to increase over the course of the forecast period as more people become aware of the advantages of preventative healthcare. The market's expansion is anticipated to be fueled by government initiatives and programs that attempt to raise cancer awareness. The most common method of diagnosis for this type of cancer is a biopsy, though imaging is expected to become more common as technology advances and has an impact on the demand for leukemia therapies treatment in the near future.
High radiation exposure increases the chance of leukemia in those who are exposed. In the workplace, for example, prolonged exposure to high concentrations of solvents like benzene is a recognized risk factor. A person's risk of acquiring CLL is increased by two to four times if they have a first-degree relative who has the disease, such as a parent, child, or sibling.
But most people who get leukemia don't have a family member who has the illness. Prior to the onset of symptoms, a simple blood test can detect persistent leukemia. Cell treatments can effectively address a few unmet needs in AML. The second line of therapies and enhanced transplant outcomes are the most crucial. Numerous unclassified cell therapies are designed to close the performance gap left by allogeneic stem cell transplants. These unmet needs also offer significant growth opportunities for market growth.
The Middle East's population is aging swiftly, and since age is the main risk factor for developing cancer, its prevalence, and incidence are increasing among all of the populations in the region. These trends have caused major issues for both the national and community-based health services. The UAE government has placed a high premium on creating a world-class healthcare infrastructure, which has caused the sector to expand and develop significantly over the past several years. With the incidence of lifestyle diseases increasing, the populations with relatively high-income levels will seek higher-quality healthcare. All of these factors are anticipated to aid in the market expansion in the LAMEA region.
The Brazil market dominated the LAMEA Leukemia Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $212.8 million by 2029. The Argentina market is experiencing a CAGR of 9.8% during (2023 - 2029). Additionally, The UAE market would showcase a CAGR of 8.9% during (2023 - 2029).
Based on Drug Class, the market is segmented into Targeted Therapy & Immunotherapy and Chemotherapy. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Type, the market is segmented into Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Leukemia Therapeutics Market is Projected to reach USD 11.7 Billion by 2029, at a CAGR of 6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Targeted Therapy & Immunotherapy
- Chemotherapy
By Distribution Channel
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Providers
By Type
- Chronic Lymphocytic Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Acute Myeloid Leukemia
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Gilead Sciences, Inc.
- Bristol Myers Squibb Company
- Sanofi S.A.
- AbbVie, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Lupin Limited
- Amgen, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Novartis AG
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Leukemia Therapeutics Market, by Drug Class
1.4.2 LAMEA Leukemia Therapeutics Market, by Distribution Channel
1.4.3 LAMEA Leukemia Therapeutics Market, by Type
1.4.4 LAMEA Leukemia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals & Trails
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May – 2022, Dec) Leading Players
Chapter 4. LAMEA Leukemia Therapeutics Market by Drug Class
4.1 LAMEA Targeted Therapy & Immunotherapy Market by Country
4.2 LAMEA Chemotherapy Market by Country
Chapter 5. LAMEA Leukemia Therapeutics Market by Distribution Channel
5.1 LAMEA Hospital Pharmacies Market by Country
5.2 LAMEA Drug Store & Retail Pharmacies Market by Country
5.3 LAMEA Online Providers Market by Country
Chapter 6. LAMEA Leukemia Therapeutics Market by Type
6.1 LAMEA Chronic Lymphocytic Leukemia Market by Country
6.2 LAMEA Acute Lymphocytic Leukemia Market by Country
6.3 LAMEA Chronic Myeloid Leukemia Market by Country
6.4 LAMEA Acute Myeloid Leukemia Market by Country
6.5 LAMEA Others Market by Country
Chapter 7. LAMEA Leukemia Therapeutics Market by Country
7.1 Brazil Leukemia Therapeutics Market
7.1.1 Brazil Leukemia Therapeutics Market by Drug Class
7.1.2 Brazil Leukemia Therapeutics Market by Distribution Channel
7.1.3 Brazil Leukemia Therapeutics Market by Type
7.2 Argentina Leukemia Therapeutics Market
7.2.1 Argentina Leukemia Therapeutics Market by Drug Class
7.2.2 Argentina Leukemia Therapeutics Market by Distribution Channel
7.2.3 Argentina Leukemia Therapeutics Market by Type
7.3 UAE Leukemia Therapeutics Market
7.3.1 UAE Leukemia Therapeutics Market by Drug Class
7.3.2 UAE Leukemia Therapeutics Market by Distribution Channel
7.3.3 UAE Leukemia Therapeutics Market by Type
7.4 Saudi Arabia Leukemia Therapeutics Market
7.4.1 Saudi Arabia Leukemia Therapeutics Market by Drug Class
7.4.2 Saudi Arabia Leukemia Therapeutics Market by Distribution Channel
7.4.3 Saudi Arabia Leukemia Therapeutics Market by Type
7.5 South Africa Leukemia Therapeutics Market
7.5.1 South Africa Leukemia Therapeutics Market by Drug Class
7.5.2 South Africa Leukemia Therapeutics Market by Distribution Channel
7.5.3 South Africa Leukemia Therapeutics Market by Type
7.6 Nigeria Leukemia Therapeutics Market
7.6.1 Nigeria Leukemia Therapeutics Market by Drug Class
7.6.2 Nigeria Leukemia Therapeutics Market by Distribution Channel
7.6.3 Nigeria Leukemia Therapeutics Market by Type
7.7 Rest of LAMEA Leukemia Therapeutics Market
7.7.1 Rest of LAMEA Leukemia Therapeutics Market by Drug Class
7.7.2 Rest of LAMEA Leukemia Therapeutics Market by Distribution Channel
7.7.3 Rest of LAMEA Leukemia Therapeutics Market by Type
Chapter 8. Company Profiles
8.1 Gilead Sciences, Inc.
8.1.1 Company overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisition and Mergers:
8.2 Bristol Myers Squibb Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.5.2 Partnerships, Collaborations and Agreements:
8.2.5.3 Approvals and Trials:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.3.5.3 Acquisitions and Mergers:
8.4 AbbVie, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.5.2 Approvals & Trials:
8.5 Teva Pharmaceutical Industries Ltd.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Product Launches and Product Expansions:
8.6 Lupin Limited
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Recent strategies and developments:
8.6.3.1 Product Launches and Product Expansions:
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Trials and Approvals:
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Approvals & Trials:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Approvals & Trials:
8.9.5.2 Acquisition and Mergers:
8.10. Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Approvals & Trials:
TABLE 1 LAMEA Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Leukemia Therapeutics Market
TABLE 4 Product Launches And Product Expansions– Leukemia Therapeutics Market
TABLE 5 Acquisition and Mergers– Leukemia Therapeutics Market
TABLE 6 Approvals & Trials– Leukemia Therapeutics Market
TABLE 7 LAMEA Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 8 LAMEA Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 9 LAMEA Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 11 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 LAMEA Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 13 LAMEA Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 14 LAMEA Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 15 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 17 LAMEA Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 19 LAMEA Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 21 LAMEA Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 22 LAMEA Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 23 LAMEA Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 25 LAMEA Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 27 LAMEA Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 28 LAMEA Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 29 LAMEA Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 30 LAMEA Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 31 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 32 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 33 LAMEA Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 34 LAMEA Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 35 Brazil Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 36 Brazil Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 37 Brazil Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 38 Brazil Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 39 Brazil Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 40 Brazil Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 41 Brazil Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 42 Brazil Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 43 Argentina Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 44 Argentina Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 45 Argentina Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 46 Argentina Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 47 Argentina Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 Argentina Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 49 Argentina Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 50 Argentina Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 51 UAE Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 52 UAE Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 53 UAE Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 54 UAE Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 55 UAE Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 56 UAE Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 57 UAE Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 58 UAE Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 59 Saudi Arabia Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 60 Saudi Arabia Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 61 Saudi Arabia Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 62 Saudi Arabia Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 63 Saudi Arabia Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 64 Saudi Arabia Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 65 Saudi Arabia Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 66 Saudi Arabia Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 67 South Africa Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 68 South Africa Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 69 South Africa Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 70 South Africa Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 71 South Africa Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 72 South Africa Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 73 South Africa Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 74 South Africa Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 75 Nigeria Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 76 Nigeria Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 77 Nigeria Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 78 Nigeria Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 79 Nigeria Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 80 Nigeria Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 81 Nigeria Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 82 Nigeria Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 83 Rest of LAMEA Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 84 Rest of LAMEA Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 85 Rest of LAMEA Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 86 Rest of LAMEA Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 87 Rest of LAMEA Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 88 Rest of LAMEA Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 89 Rest of LAMEA Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 90 Rest of LAMEA Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 91 Key Information – Gilead Sciences, Inc.
TABLE 92 Key Information – Bristol Myers Squibb Company
TABLE 93 Key Information – Sanofi S.A.
TABLE 94 Key information – AbbVie, Inc.
TABLE 95 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 96 Key Information – Lupin Limited
TABLE 97 Key Information – Amgen, Inc.
TABLE 98 Key Information – Takeda Pharmaceutical Company Limited
TABLE 99 Key Information – Pfizer, Inc.
TABLE 100 Key Information – Novartis AG
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May – 2022, Dec) Leading Players
FIG 5 LAMEA Leukemia Therapeutics Market Share by Drug Class, 2022
FIG 6 LAMEA Leukemia Therapeutics Market Share by Drug Class, 2029
FIG 7 LAMEA Leukemia Therapeutics Market by Drug Class, 2019 - 2029, USD Million
FIG 8 LAMEA Leukemia Therapeutics Market Share by Distribution Channel, 2022
FIG 9 LAMEA Leukemia Therapeutics Market Share by Distribution Channel, 2029
FIG 10 LAMEA Leukemia Therapeutics Market by Distribution Channel, 2019 - 2029, USD Million
FIG 11 LAMEA Leukemia Therapeutics Market Share by Type, 2022
FIG 12 LAMEA Leukemia Therapeutics Market Share by Type, 2029
FIG 13 LAMEA Leukemia Therapeutics Market by Type, 2019 - 2029, USD Million
FIG 14 LAMEA Leukemia Therapeutics Market Share by Country, 2022
FIG 15 LAMEA Leukemia Therapeutics Market Share by Country, 2029
FIG 16 LAMEA Leukemia Therapeutics Market by Country, 2019 - 2029, USD Million
FIG 17 Recent strategies and developments: Gilead Sciences, Inc.
FIG 18 Recent strategies and developments: Bristol Myers Squibb Company
FIG 19 Recent strategies and developments: Sanofi S.A.